Combination Treatment Strategies With Peptide Receptor Radionuclide Therapy
- 3 August 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (9) , e846-e864
Abstract
The landscape of systemic treatment for patients with neuroendocrine tumors (NET) is continuously evolving due to discovery of various molecular pathways involvement in tumor growth and the clinical availability of several therapeutic agents against these pathways. Among these agents, peptide receptor radionuclide therapy (PRRT) serves as the cornerstone for the treatment of well-differentiated metastatic/advanced NETs that express somatostatin receptors (SSTR). However, complete response and longer survival rates with progression-free disease status after PRRT are rarely observed. Therefore, a combination of PRRT with other antitumor agents exhibiting synergistic effects is necessary to augment PRRT efficacy without increasing the toxicity profile. Various combinations of PRRT with antitumor agents or surgical intervention have been employed, including somatostatin analogs (SSAs), radiosensitizing chemotherapy, cytotoxic chemotherapy, different therapeutic isotopes, transarterial radioembolization (TARE), targeted molecular drugs, immune-checkpoint inhibitors (ICIs), and neoadjuvant PRRT before surgery. This review will explore various combinations of PRRT with other antitumor agents, highlighting their fundamental mechanisms of action for synergistic effects. It will also focus on protocols for combined PRRT approaches, provide an overview of existing literature and ongoing clinical trials, discuss the future directions and perspectives, and offer insights into the practical use of combination strategies in various clinical scenarios to assist clinicians in planning effective and safe combined treatment regimens for the management of NET patients.Keywords
This publication has 58 references indexed in Scilit:
- Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experienceEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Availability of both [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?European Journal of Nuclear Medicine and Molecular Imaging, 2019
- Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluationEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)European Journal of Nuclear Medicine and Molecular Imaging, 2014
- Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?European Journal of Nuclear Medicine and Molecular Imaging, 2011
- Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomasCancer, 2010
- 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotideEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008